Effect of Focal and Grid Pattern PASCAL Photocoagulation Treatment in Diabetic Macular Edema

Jae Kwan Park; Woo Jin Jeung

doi:10.3341/jkos.2011.52.2.197

Journal List > J Korean Ophthalmol Soc > v.52(2) > 1008972

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park and Jeung: Effect of Focal and Grid Pattern PASCAL Photocoagulation Treatment in Diabetic Macular Edema

Original Article

J Korean Ophthalmol Soc 2011;52(2):197-202.

Published online: 7 September 2011

DOI: https://doi.org/10.3341/jkos.2011.52.2.197

Effect of Focal and Grid Pattern PASCAL Photocoagulation Treatment in Diabetic Macular Edema

Jae Kwan Park, MD, Woo Jin Jeung, MD

Department of Ophthalmology, Dong-A University College of Medicine, Busan, Korea

Address reprint requests to Woo Jin Jeung, MD Department of Ophthalmology, Dong-A University Hospital #3-1 Dongdaesin-dong, Seo-gu, Busan 602-715, Korea Tel: 82-51-240-5227, Fax: 82-51-254-1987, E-mail: wjeye@dau.ac.kr

Received 5 July 201024 September 2010 Accepted 29 November 2010

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To investigate the effect of focal and grid pattern PASCAL photocoagulation treatment in diabetic macular edema patients.

Methods

A total of 72 patients (75 eyes) who were diagnosed as diabetic macular edema were retrospectively analyzed. The patients were divided into 3 groups as follows: group 1 (31 patients, 31 eyes) received an intravitreal bevacizumab injection, group 2 (17 patients, 20 eyes) underwent focal and grid pattern PASCAL photocoagulation treatment, and group 3 (24 patients, 24 eyes) underwent focal and grid pattern argon photocoagulation treatment. Macular thickness and visual acuity (logMAR) of 75 eyes were compared among groups before and after treatments.

Results

Visual acuity improved in 13 eyes (65.0%) in group 1, 16 eyes (51.6%) in group 2, and in 10 eyes (41.6%) in group 3; however, there was no statistical significance. Macular thickness reduction occurred in 24 eyes (77.4%) in group 1 and 13 eyes (65.0%) in group 2 which were statistically significant decreases at only 1 month after treatment (p < 0.05).

Conclusions

Focal and grid pattern PASCAL photocoagulation is a good therapeutic option for diabetic macular edema. Focal and grid pattern PASCAL photocoagulation is as effective as intravitreal bevacizumab injection or focal and grid pattern argon photocoagulation treatment.

Keywords: Diabetic macular edema, Pascal photocoagulation

References

1. Ryan SJ. Nonproliferative diabetic retinopathy. Chew EY, Ferris FL III, editors. Retina. 4th ed.New York: Mosby, Elsevier Inc.;2006. 2:chap. 67.

2. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no 2. Ophthalmology. 1987; 94:761–74.

3. Early Treatment Diabetic Retinopathy Study Research Group. ETDRS report no. 1: photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985; 103:1796–806.

4. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005; 36:331–5.

5. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363–72.

6. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006; 26:352–4.

7. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26:275–8.

8. Blumenkranz MS, Yellachich D, Andersen DE, et al. Semiautomated patterned scanning laser for retinal photocoagulation. Retina. 2006; 26:370–6.

9. Sanghvi C, McLauchlan R, Delgado C, et al. Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol. 2008; 92:1061–4.

10. Cho BJ, Kim TW, Woo SJ, et al. Short-term clinical outcome of patterned scanning laser photocoagulation with short exposure time in diabetic retinopathy. J Korean Ophthalmol Soc. 2009; 50:376–82.

11. Kim HK, Han YB. Laser photocoagulation in diabetic macular edema. J Korean Ophthalmol Soc. 1992; 33:759–63.

12. Bresnick GH. Diabetic maculopathy; a critical review highlighting diffuse macular edema. Ophthalmology. 1983; 90:1301–17.

13. Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1986; 93:938–50.

14. Townsend C, Bailey J, Kohner E. Xenon arc photocoagulation for the treatment of diabetic maculopathy. Interim report of a multi-centre controlled clinical study. Br J Ophthalmol. 1980; 64:385–91.

15. Blankenship GW. Diabetic macular edema and argon laser photocoagulation: a prospective randomized study. Ophthalmology. 1979; 86:69–78.

16. Bresnick GH. Nonproliferative diabetic retinopathy. Ryan SJ, editor. Retina. 2nd ed.St. Louis: CV Mosby;1994. p. 1277–318.

17. Shahidi M, Ogura Y, Blair NP, Zeimer R. Retinal thickness change after focal laser treatment of diabetic macular edema. Br J Ophthalmol. 1994; 78:827–30.

18. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335–42.

19. Brooks HL, Caballero S, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004; 122:1801–7.

Figure 1.

When the ‘A’ format of a grid pattern is selected it will advance to the ‘B’ format automatically after firing. If a user start with the ‘B’ format, it will not advance to ‘A’ after firing.

Figure 2.

Visual acuity (logMAR).

Figure 3.

Macular thickness (μ m).

Table 1.

Characteristics of patients before treatments

Number of eyes	75
Gender
Male (eyes)	42
Female (eyes)	33
Age (yr, mean ± SD)	60.15 ± 8.73
Visual acuity (logMAR, mean ± SD)	0.72 ± 0.25
Macular thickness (µm, mean ± SD))	362.04 ± 105.33

Table 2.

Visual acuity (logMAR)

	Group 1	Group 2	Group 3
Before Treatment	0.82 ± 0.20	0.67 ± 0.19	0.65 ± 0.31
After Treatment
1 month	0.78 ± 0.22	0.65 ± 0.21	0.61 ± 0.30
p-value	0.274	0.464	0.129
3 months	0.78 ± 0.21	0.63 ± 0.23	0.58 ± 0.30
p-value	0.445	0.483	0.012
6 months	0.78 ± 0.21	0.64 ± 0.25	0.59 ± 0.31
p-value	0.325	0.924	0.175

Table 3.

Macular thickness (µ m)

	Group 1	Group 2	Group 3
Before treatment	394.26 ± 325.58	354.75 ± 116.82	342.58 ± 93.26
After treatment
1 month	325.58 ± 121.74	281.40 ± 66.04	286.29 ± 104.49
p-value	0.002	0.001	0.006
3 months	355.50 ± 127.77	309.47 ± 71.56	302.93 ± 110.44
p-value	0.077	0.112	0.075
6 months	324.94 ± 86.90	320.75 ± 73.12	337.85 ± 86.90
p-value	0.003	0.313	0.221

TOOLS

Similar articles